Phase 4 Motor Neurone Disease Trial, Recruiting NCT05923905 Sponsor: Peking University Third Hospital Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Phase 4 Motor Neurone Disease Trial, Recruiting

NCT05923905
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ALS (Amyotrophic Lateral Sclerosis), either inherited or non-inherited, confirmed using standard medical guidelines
  • You are between 18 and 80 years old
  • Your ALS symptoms started no more than 18 months ago
  • Your ALS function rating score is at or above a certain level, meaning your daily abilities (including breathing) are still relatively preserved (confirm with trial site)
  • Your lung capacity is at least 70% of what would be expected for someone of your age, height, and gender
  • A brain activity (EEG) analysis using AI shows a specific pattern related to low mood or depression (confirm with trial site)
  • If you are able to have children (male or female), you agree to use an accepted form of contraception during the trial
  • You are willing to take part voluntarily and sign a consent form

Who may not be able to join:

  • You have dementia, or a serious brain, mental health, or other medical condition that is poorly controlled or could affect the trial
  • You are currently pregnant or breastfeeding
  • You have a history of attempted suicide
  • You have another neurological condition with symptoms similar to ALS, such as spine-related nerve problems or dementia
  • You have had spinal surgery after your ALS diagnosis
  • Your liver or kidney function tests fall outside acceptable ranges (confirm with trial site)
  • You have a known allergy to the medication being tested in this trial
  • You have taken part in another clinical trial within the last 3 months
  • The trial doctor has another reason they feel you are not suitable for this study

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Fan DongSheng, Peking University Third Hospital

Phone: +86-10-82265791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
18 January 2023
Est. completion
30 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ROADS (Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov